Immunotherapy in Glioblastoma: An Overview of Current Status
Zouina Sarfraz,1 Arun Maharaj,1 Vyshak Alva Venur,2 Justin D Lathia,3 Yazmin Odia,1 Manmeet S Ahluwalia1,4 1Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA; 2Seattle Cancer Care Alliance, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA; 3Cleveland Clini...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-07-01
|
| Series: | Clinical Pharmacology: Advances and Applications |
| Subjects: | |
| Online Access: | https://www.dovepress.com/immunotherapy-in-glioblastoma-an-overview-of-current-status-peer-reviewed-fulltext-article-CPAA |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849420337704337408 |
|---|---|
| author | Sarfraz Z Maharaj A Venur VA Lathia JD Odia Y Ahluwalia MS |
| author_facet | Sarfraz Z Maharaj A Venur VA Lathia JD Odia Y Ahluwalia MS |
| author_sort | Sarfraz Z |
| collection | DOAJ |
| description | Zouina Sarfraz,1 Arun Maharaj,1 Vyshak Alva Venur,2 Justin D Lathia,3 Yazmin Odia,1 Manmeet S Ahluwalia1,4 1Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA; 2Seattle Cancer Care Alliance, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA; 3Cleveland Clinic Research, Cleveland, OH, USA; 4Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USACorrespondence: Manmeet S Ahluwalia MD, MBA, FASCO, Fernandez Family Foundation Endowed Chair in Cancer Research, Chief of Medical Oncology, Chief Scientific Officer & Deputy Director,Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA, Tel +1-786-527-8010, Fax +1-786-533-9416, Email manmeeta@baptisthealth.netAbstract: Glioblastoma (GB) is an aggressive brain tumor with standard therapies offering limited but measurable survival benefit. Immunotherapy is expanding the treatment landscape for GB. Immune checkpoint inhibitors (ICIs), including nivolumab and pembrolizumab, have shown benefit in several cancers and are being studied in GB, with ongoing efforts to address the tumor’s immunosuppressive environment. Chimeric Antigen Receptor (CAR) T-cell therapies are also being explored, with new approaches designed to overcome antigen variability and improve access across the blood-brain barrier. Cancer vaccines, especially dendritic cell-based platforms like DCVax-L, have shown promising survival outcomes in clinical trials. Advances in biomarker analysis and genomics are supporting more personalized immunotherapy approaches. In addition, combination strategies involving ICIs, CAR T-cells, vaccines, and oncolytic viruses are being developed to enhance immune response. This review outlines current immunotherapy approaches in GB, focusing on their mechanisms, clinical development, and future directions.Plain Language Summary: Glioblastoma (GB) is an aggressive and common type of brain cancer, with current treatments offering modest survival benefits. Standard treatments like surgery, chemotherapy, and radiation therapy are not enough to stop the tumor from coming back. Because of this, researchers are exploring new approaches, including immunotherapy, which uses the body’s immune system to fight cancer. Immunotherapy has shown success in treating other cancers, but GB presents unique challenges. The tumor creates an environment that weakens the immune response and prevents treatments from working effectively. This review explores different types of immunotherapy being tested for GB:Immune checkpoint inhibitors (ICIs): Drugs like nivolumab and pembrolizumab help the immune system recognize and attack GB cells. However, clinical trials show only modest improvements in survival.CAR T-cell therapy: This treatment modifies a patient’s immune cells to better target the tumor. While promising, barriers like tumor diversity and the brain’s natural defenses make it difficult for CAR T-cells to work effectively.Cancer vaccines: These aim to train the immune system to recognize GB cells as threats, but results have been mixed, with some showing potential for improving survival.Oncolytic viruses: These viruses selectively infect and kill cancer cells while stimulating an immune response. Early trials suggest they may help when combined with other treatments.Keywords: glioblastoma, immunotherapy, tumor microenvironment, antigen heterogeneity, personalized treatment, blood-brain barrier |
| format | Article |
| id | doaj-art-e07942a1e7a545cbbc68b9eaae8ff33f |
| institution | Kabale University |
| issn | 1179-1438 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Pharmacology: Advances and Applications |
| spelling | doaj-art-e07942a1e7a545cbbc68b9eaae8ff33f2025-08-20T03:31:46ZengDove Medical PressClinical Pharmacology: Advances and Applications1179-14382025-07-01Volume 17Issue 1185209105126Immunotherapy in Glioblastoma: An Overview of Current StatusSarfraz Z0Maharaj A1Venur VA2Lathia JD3Odia Y4Ahluwalia MS5Medical OncologyResearchMedical OncologyRose Ella Burkhardt Brain Tumor and Neuro-Oncology CenterNeuro-OncologyMedical OncologyZouina Sarfraz,1 Arun Maharaj,1 Vyshak Alva Venur,2 Justin D Lathia,3 Yazmin Odia,1 Manmeet S Ahluwalia1,4 1Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA; 2Seattle Cancer Care Alliance, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA; 3Cleveland Clinic Research, Cleveland, OH, USA; 4Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USACorrespondence: Manmeet S Ahluwalia MD, MBA, FASCO, Fernandez Family Foundation Endowed Chair in Cancer Research, Chief of Medical Oncology, Chief Scientific Officer & Deputy Director,Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA, Tel +1-786-527-8010, Fax +1-786-533-9416, Email manmeeta@baptisthealth.netAbstract: Glioblastoma (GB) is an aggressive brain tumor with standard therapies offering limited but measurable survival benefit. Immunotherapy is expanding the treatment landscape for GB. Immune checkpoint inhibitors (ICIs), including nivolumab and pembrolizumab, have shown benefit in several cancers and are being studied in GB, with ongoing efforts to address the tumor’s immunosuppressive environment. Chimeric Antigen Receptor (CAR) T-cell therapies are also being explored, with new approaches designed to overcome antigen variability and improve access across the blood-brain barrier. Cancer vaccines, especially dendritic cell-based platforms like DCVax-L, have shown promising survival outcomes in clinical trials. Advances in biomarker analysis and genomics are supporting more personalized immunotherapy approaches. In addition, combination strategies involving ICIs, CAR T-cells, vaccines, and oncolytic viruses are being developed to enhance immune response. This review outlines current immunotherapy approaches in GB, focusing on their mechanisms, clinical development, and future directions.Plain Language Summary: Glioblastoma (GB) is an aggressive and common type of brain cancer, with current treatments offering modest survival benefits. Standard treatments like surgery, chemotherapy, and radiation therapy are not enough to stop the tumor from coming back. Because of this, researchers are exploring new approaches, including immunotherapy, which uses the body’s immune system to fight cancer. Immunotherapy has shown success in treating other cancers, but GB presents unique challenges. The tumor creates an environment that weakens the immune response and prevents treatments from working effectively. This review explores different types of immunotherapy being tested for GB:Immune checkpoint inhibitors (ICIs): Drugs like nivolumab and pembrolizumab help the immune system recognize and attack GB cells. However, clinical trials show only modest improvements in survival.CAR T-cell therapy: This treatment modifies a patient’s immune cells to better target the tumor. While promising, barriers like tumor diversity and the brain’s natural defenses make it difficult for CAR T-cells to work effectively.Cancer vaccines: These aim to train the immune system to recognize GB cells as threats, but results have been mixed, with some showing potential for improving survival.Oncolytic viruses: These viruses selectively infect and kill cancer cells while stimulating an immune response. Early trials suggest they may help when combined with other treatments.Keywords: glioblastoma, immunotherapy, tumor microenvironment, antigen heterogeneity, personalized treatment, blood-brain barrierhttps://www.dovepress.com/immunotherapy-in-glioblastoma-an-overview-of-current-status-peer-reviewed-fulltext-article-CPAAGlioblastomaimmunotherapytumor microenvironmentantigen heterogeneitypersonalized treatmentblood-brain barrier. |
| spellingShingle | Sarfraz Z Maharaj A Venur VA Lathia JD Odia Y Ahluwalia MS Immunotherapy in Glioblastoma: An Overview of Current Status Clinical Pharmacology: Advances and Applications Glioblastoma immunotherapy tumor microenvironment antigen heterogeneity personalized treatment blood-brain barrier. |
| title | Immunotherapy in Glioblastoma: An Overview of Current Status |
| title_full | Immunotherapy in Glioblastoma: An Overview of Current Status |
| title_fullStr | Immunotherapy in Glioblastoma: An Overview of Current Status |
| title_full_unstemmed | Immunotherapy in Glioblastoma: An Overview of Current Status |
| title_short | Immunotherapy in Glioblastoma: An Overview of Current Status |
| title_sort | immunotherapy in glioblastoma an overview of current status |
| topic | Glioblastoma immunotherapy tumor microenvironment antigen heterogeneity personalized treatment blood-brain barrier. |
| url | https://www.dovepress.com/immunotherapy-in-glioblastoma-an-overview-of-current-status-peer-reviewed-fulltext-article-CPAA |
| work_keys_str_mv | AT sarfrazz immunotherapyinglioblastomaanoverviewofcurrentstatus AT maharaja immunotherapyinglioblastomaanoverviewofcurrentstatus AT venurva immunotherapyinglioblastomaanoverviewofcurrentstatus AT lathiajd immunotherapyinglioblastomaanoverviewofcurrentstatus AT odiay immunotherapyinglioblastomaanoverviewofcurrentstatus AT ahluwaliams immunotherapyinglioblastomaanoverviewofcurrentstatus |